Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2015

View Archived Issues

biOasis Technologies and Brigham and Women's Hospital form neuro-oncology R&D agreement

Lilly divulges several analyses of phase III solanezumab trial data

Allogeneic mesenchymal precursor cells show promising results for the treatment of type 2 diabetes

ASK-1 inhibition protects mice from thrombosis

Lpath receives FDA clearance to start phase I trial of Lpathomab

Lupin to acquire Gavis

Researchers publish preclinical data that led to advancement of antimalarial agent DSM-265

Bausch + Lomb submits Vesneo NDA

Zalviso recommended for approval in Europe

EMA committee grants accelerated assessment to ixazomib for relapsed/refractory multiple myeloma

FDA approves Odomzo for locally advanced BCC

Biohaven files IND for BHV-0223 for treatment-resistant affective disorders

Algomedix presents TRPA1 antagonists

Bristol-Myers Squibb patents ROR-gamma modulators

Blend Therapeutics divulges platinum complexes for cancer

Jiangsu Hansoh Pharmaceutical Group introduces NS5B inhibitors

Rhizen Pharmaceuticals patents glutaminase inhibitors

FDA approves Technivie for genotype 4 chronic HCV infection

Genentech to advance crenezumab into phase III for prodromal to mild Alzheimer's disease

EMA committee recommends approval of Fexeric

FDA approves Praluent to treat high LDL cholesterol

EMA committee recommends approval of Intuniv for ADHD in children and adolescents

FDA approves Daklinza for genotype 3 chronic HCV infection

Genzyme to acquire vandetanib from AstraZeneca

EMA Committee hands down positive opinion for Revolade in severe aplastic anemia

FDA approves Kyprolis in combination use for relapsed multiple myeloma

Omeros's OMS-721 receives fast track designation for aHUS

European recommendation, U.S. priority review for Tafinlar and Mekinist combination

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...